VEDANTA BIOSCIENCES

vedanta-biosciences-logo

Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. It includes a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing of rationally defined bacterial consortia in powder form to help physicians have access to live bacteria drugs to treat autoimmune and inflammatory diseases easily.

#SimilarOrganizations #People #Financial #Event #Website #More

VEDANTA BIOSCIENCES

Social Links:

Industry:
Biotechnology Business Development Medical

Founded:
2010-01-01

Address:
Cambridge, Massachusetts, United States

Country:
United States

Website Url:
http://www.vedantabio.com

Total Employee:
101+

Status:
Active

Contact:
(857)706-1427

Email Addresses:
[email protected]

Total Funding:
436.99 M USD

Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving SPF Apple Mobile Web Clips Icon Google Font API Google Analytics Content Delivery Network LetsEncrypt Amazon


Similar Organizations

eikon-therapeutics-logo

Eikon Therapeutics

Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery.

excision-biotherapeutics-logo

Excision BioTherapeutics

Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.

expresscells-logo

ExpressCells

ExpressCells creates custom cell lines for biological research and drug discovery.

fauna-bio-logo

Fauna Bio

Fauna Bio is a biotechnology company leveraging the science of hibernation to improve healthcare for humans.

pionyr-immunotherapeutics-logo

Pionyr Immunotherapeutics

Pionyr Immunotherapeutics is a developer of cancer immunotherapies designed to target the tumor microenvironment.

slingshot-biosciences-logo

Slingshot Biosciences

Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.

verismo-therapeutics-logo

Verismo Therapeutics

Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer.


Current Advisors List

ben-shapiro_image

Ben Shapiro Board Member @ Vedanta Biosciences
Board_member

john-lamattina_image

John LaMattina Member of the BOD @ Vedanta Biosciences
Board_member

chris-viehbacher_image

Chris Viehbacher Chairman of the BOD @ Vedanta Biosciences
Board_member
2015-05-01

curt-labelle_image

Curt LaBelle Board Member @ Vedanta Biosciences
Board_member
2023-04-01

neil-tiwari_image

Neil Tiwari Board Member @ Vedanta Biosciences
Board_member
2023-04-01

troy-ignelzi_image

Troy Ignelzi Board Member @ Vedanta Biosciences
Board_member
2020-11-01

martin-heidecker_image

Martin Heidecker Board Member @ Vedanta Biosciences
Board_member
2023-04-01

Current Employees Featured

alexander-rudensky_image

Alexander Rudensky
Alexander Rudensky Scientific Co-Founder @ Vedanta Biosciences
Scientific Co-Founder

dan-littman_image

Dan Littman
Dan Littman Scientific Co-Founder @ Vedanta Biosciences
Scientific Co-Founder

bernat-olle_image

Bernat Olle
Bernat Olle CEO, Co-founder & Board of Directors @ Vedanta Biosciences
CEO, Co-founder & Board of Directors
2015-09-01

ruslan-medzhitov_image

Ruslan Medzhitov
Ruslan Medzhitov Co-Founder & Chair @ Vedanta Biosciences
Co-Founder & Chair

daniel-couto_image

Daniel Couto
Daniel Couto Chief Operating Officer @ Vedanta Biosciences
Chief Operating Officer
2019-10-01

silvia-caballero_image

Silvia Caballero
Silvia Caballero Director, Infectious Diseases @ Vedanta Biosciences
Director, Infectious Diseases
2021-04-01

jeffrey-silber_image

Jeffrey Silber
Jeffrey Silber CMO @ Vedanta Biosciences
CMO
2020-01-01

simona-levi_image

Simona Levi
Simona Levi Chief Legal Officer @ Vedanta Biosciences
Chief Legal Officer
2021-10-01

Founder


alexander-rudensky_image

Alexander Rudensky

bernat-olle_image

Bernat Olle

dan-littman_image

Dan Littman

david-steinberg_image

David Steinberg

ruslan-medzhitov_image

Ruslan Medzhitov

Investors List

carb-x_image

CARB-X

CARB-X investment in Grant - Vedanta Biosciences

colorcon-ventures_image

Colorcon Ventures

Colorcon Ventures investment in Venture Round - Vedanta Biosciences

fiscus-ventures_image

Fiscus Ventures

Fiscus Ventures investment in Series E - Vedanta Biosciences

puretech-ventures_image

PureTech Health

PureTech Health investment in Series E - Vedanta Biosciences

skyviews-life-science_image

Skyviews Life Science

Skyviews Life Science investment in Series E - Vedanta Biosciences

atlantic-neptune_image

Atlantic Neptune

Atlantic Neptune investment in Series E - Vedanta Biosciences

peak6-investments_image

Peak 6

Peak 6 investment in Series E - Vedanta Biosciences

amr-action-fund_image

AMR Action Fund

AMR Action Fund investment in Series E - Vedanta Biosciences

revelation-partners_image

Revelation Partners

Revelation Partners investment in Series E - Vedanta Biosciences

korea-investment-holdings_image

Korea Investment Holdings

Korea Investment Holdings investment in Series E - Vedanta Biosciences

Official Site Inspections

http://www.vedantabio.com Semrush global rank: 1.1 M Semrush visits lastest month: 25.05 K

  • Host name: ec2-54-208-101-55.compute-1.amazonaws.com
  • IP address: 54.208.101.55
  • Location: Ashburn United States
  • Latitude: 39.0481
  • Longitude: -77.4728
  • Metro Code: 511
  • Timezone: America/New_York
  • Postal: 20149

Loading ...

More informations about "Vedanta Biosciences"

Vedanta Biosciences, Inc.

Advancing the Treatment of Gastrointestinal Diseases Using Defined Bacterial Consortia. ยฉ 2024 Vedanta Biosciences, Inc. All Rights Reserved.See details»

Careers - Vedanta Biosciences, Inc.

We are enabling this new drug class with groundbreaking and industry-leading scientific work powered by large-scale capabilities to identify, screen, and manufacture bacteria with drug-like โ€ฆSee details»

Vedanta Biosciences - Crunchbase Company Profile

Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. It includes a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets โ€ฆSee details»

Vedanta Biosciences Company Profile 2024: Valuation, โ€ฆ

Developer of orally delivered defined bacterial consortia designed to treat inflammatory and infectious diseases.See details»

Vedanta Biosciences, Inc. | LinkedIn

Vedanta is developing a novel class of therapies that modulate pathways of interaction between the human microbiome and the host immune system. Vedanta was co-founded by PureTech Health and a...See details»

Vedanta Biosciences Inc - Company Profile and News

The Company design and develops medicines based on consortia of human commensal bacteria to treat a range of gastrointestinal diseases, using insights from microbial ecology, mucosal โ€ฆSee details»

Vedanta Biosciences โ€“ Right Partner For Your Chemistry Solutions

Vedanta Biosciences is a Hyderabad based Contract Research Organization (CRO) serving as an outsourcing partner for the biotech, pharmaceutical industries and research institutions. โ€ฆSee details»

Vedanta Biosciences - Overview, News & Similar companies

May 21, 2024ย ยท Vedanta Biosciences contact info: Phone number: (857) 706-1427 Website: www.vedantabio.com What does Vedanta Biosciences do? Founded in 2010, Vedanta โ€ฆSee details»

Vedanta Biosciences Announces $25 Million Investment from โ€ฆ

CAMBRIDGE, January 12, 2021 โ€“ Vedanta Biosciences, a leading clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally โ€ฆSee details»

Vedanta Biosciences - Craft

Vedanta Biosciences was founded by PureTech and a team of world renowned experts in immunology and microbiology. Vedanta Biosciences is developing a class of drugs that work โ€ฆSee details»

Vedanta Biosciences CEO and Key Executive Team | Craft.co

Vedanta Biosciences's key executives include Bernat Olle and 16 others. Need Data? Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via โ€ฆSee details»

Vedanta Biosciences - VentureRadar

"Vedanta Biosciences is a clinical-stage microbiome leader developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human โ€ฆSee details»

Vedanta Biosciences - Work in biotech

Vedanta has one of the largest, most diverse culture collections of gut bacteria in the world and is using their discovery platform to identify defined bacterial consortia with drug-like properties โ€ฆSee details»

Vedanta Biosciences Announces Initiation of First-in-Patient Study โ€ฆ

CAMBRIDGE, Mass., Dec. 10, 2019 โ€” Vedanta Biosciences, Inc. (Vedanta Biosciences, Vedanta or the Company), a clinical-stage biopharmaceutical company developing a new category of โ€ฆSee details»

Vedanta Biosciences Announces First Patient Dosed in Phase 2 โ€ฆ

Oct 4, 2023ย ยท CAMBRIDGE, Mass.-- ( BUSINESS WIRE )-- Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined โ€ฆSee details»

Vedanta Biosciences Announces $25 Million Investment from

Jan 12, 2021ย ยท CAMBRIDGE, Mass. -- (BUSINESS WIRE)-- Vedanta Biosciences, a leading clinical-stage company developing a new category of therapies for immune-mediated diseases โ€ฆSee details»

Working at Vedanta biosciences - Glassdoor

Mission: We believe that in the near future, doctors will have an entirely new option to treat patients: bacterial consortia therapeutics. We are enabling this new drug class with โ€ฆSee details»

Press Releases :: Vedanta Biosciences, Inc.

Oct 16, 2024ย ยท Oct 11, 2023 Vedanta Biosciences Presents Progress from Two Defined Bacterial Consortia, VE303 for the Prevention of C. difficile and VE707 for the Prevention of Gram โ€ฆSee details»

Vedanta Biosciences Completes $68 Million Series D Financing

Jul 21, 2021ย ยท Vedanta has received funding from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) of up to $7.4 million, plus up to $3.5 million more if โ€ฆSee details»

Product Engine :: Vedanta Biosciences, Inc.

Our field-leading product engine enables identification of defined bacterial consortia with drug-like properties and their manufacture to CGMP standards. Gut dysbiosis is a known driver of โ€ฆSee details»

linkstock.net © 2022. All rights reserved